Germline O
mutations O
in O
BRCA1 O
are O
responsible O
for O
most O
cases O
of O
inherited B
breast I
and I
ovarian I
cancer I
. O

As O
a O
regulated O
secretory O
protein O
, O
BRCA1 O
appears O
to O
function O
by O
a O
mechanism O
not O
previously O
described O
for O
tumour B
suppressor O
gene O
products O
. O
. O

Ovarian B
cancer I
risk O
in O
BRCA1 O
carriers O
is O
modified O
by O
the O
HRAS1 O
variable O
number O
of O
tandem O
repeat O
( O
VNTR O
) O
locus O
. O

Women O
who O
carry O
a O
mutation O
in O
the O
BRCA1 O
gene O
( O
on O
chromosome O
17q21 O
) O
, O
have O
an O
80 O
% O
risk O
of O
breast B
cancer I
and O
a O
40 O
% O
risk O
of O
ovarian B
cancer I
by O
the O
age O
of O
70 O
( O
ref O
. O
1 O
) O
. O

The O
HRAS1 O
variable O
number O
of O
tandem O
repeats O
( O
VNTR O
) O
polymorphism O
, O
located O
1 O
kilobase O
( O
kb O
) O
downstream O
of O
the O
HRAS1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O
5 O
) O
is O
one O
possible O
genetic O
modifier O
of O
cancer B
penetrance O
. O

Individuals O
who O
have O
rare O
alleles O
of O
the O
VNTR O
have O
an O
increased O
risk O
of O
certain O
types O
of O
cancers B
, O
including O
breast B
cancer I
( O
2 O
- O
4 O
) O
. O

To O
investigate O
whether O
the O
presence O
of O
rare O
HRAS1 O
alleles O
increases O
susceptibility O
to O
hereditary B
breast I
and I
ovarian I
cancer I
, O
we O
have O
typed O
a O
panel O
of O
307 O
female O
BRCA1 O
carriers O
at O
this O
locus O
using O
a O
PCR O
- O
based O
technique O
. O

The O
risk O
for O
ovarian B
cancer I
was O
2 O
. O

Susceptibility O
to O
breast B
cancer I
did O
not O
appear O
to O
be O
affected O
by O
the O
presence O
of O
rare O
HRAS1 O
alleles O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
associated O
with O
a O
( O
CTG O
) O
n O
trinucleotide O
repeat O
expansion O
in O
the O
3 O
- O
untranslated O
region O
of O
a O
protein O
kinase O
- O
encoding O
gene O
, O
DMPK O
, O
which O
maps O
to O
chromosome O
19q13 O
. O

The O
DM B
region O
of O
chromosome O
19 O
is O
gene O
rich O
, O
and O
it O
is O
possible O
that O
the O
repeat O
expansion O
may O
lead O
to O
dysfunction O
of O
a O
number O
of O
transcription O
units O
in O
the O
vicinity O
, O
perhaps O
as O
a O
consequence O
of O
chromatin O
disruption O
. O

RT O
- O
PCR O
analysis O
shows O
that O
this O
gene O
, O
which O
we O
have O
called O
DM B
locus O
- O
associated O
homeodomain O
protein O
( O
DMAHP O
) O
, O
is O
expressed O
in O
a O
number O
of O
human O
tissues O
, O
including O
skeletal O
muscle O
, O
heart O
and O
brain O
. O

Germline O
mutations O
in O
the O
RB1 O
gene O
in O
patients O
with O
hereditary B
retinoblastoma I
. O

The O
Type O
II O
C2 O
null O
allele O
( O
C2Q0 O
) O
is O
linked O
to O
two O
major O
histocompatibility O
haplotypes O
( O
MHC O
) O
that O
differ O
from O
the O
MHC O
of O
the O
more O
common O
Type B
I I
C2 I
deficiency I
. O

Subsequent O
molecular O
biology O
, O
biosynthetic O
, O
and O
immunofluorescence O
studies O
demonstrated O
that O
C2 O
secretion O
is O
impaired O
in O
Type B
II I
C2 I
deficiency I
because O
of O
different O
missense O
mutations O
at O
highly O
conserved O
residues O
in O
each O
of O
the O
C2Q0 O
alleles O
. O

Defective O
dimerization O
of O
von B
Willebrand I
factor O
subunits O
due O
to O
a O
Cys O
- O
> O
Arg O
mutation O
in O
type O
IID O
von O
Willebrand O
disease O
. O

The O
same O
heterozygous O
T O
- O
> O
C O
transition O
at O
nt O
8567 O
of O
the O
von B
Willebrand I
factor O
( O
vWF O
) O
transcript O
was O
found O
in O
two O
unrelated O
patients O
with O
type O
IID O
von O
Willebrand O
disease O
, O
with O
no O
other O
apparent O
abnormality O
. O

Wiskott B
- I
Aldrich I
syndrome I
protein O
, O
a O
novel O
effector O
for O
the O
GTPase O
CDC42Hs O
, O
is O
implicated O
in O
actin O
polymerization O
. O

We O
have O
identified O
WASP O
, O
the O
protein O
that O
is O
defective O
in O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
as O
a O
novel O
effector O
for O
CDC42Hs O
, O
but O
not O
for O
the O
other O
Rho O
family O
members O
, O
Rac O
and O
Rho O
. O

Thus O
, O
WASP O
provides O
a O
novel O
link O
between O
CDC42Hs O
and O
the O
actin O
cytoskeleton O
, O
which O
suggests O
a O
molecular O
mechanism O
for O
many O
of O
the O
cellular O
abnormalities O
in O
WAS B
. O

X B
- I
linked I
adrenoleukodystrophy I
is O
a O
frequent O
cause O
of O
idiopathic O
Addison O
' O
s O
disease O
in O
young O
adult O
male O
patients O
. O

X B
- I
Linked I
adrenoleukodystrophy I
( O
ALD B
) O
is O
a O
genetic B
disease I
associated O
with O
demyelination O
of O
the O
central O
nervous O
system O
, O
adrenal B
insufficiency I
, O
and O
accumulation O
of O
very O
long O
chain O
fatty O
acids O
in O
tissue O
and O
body O
fluids O
. O

ALD B
is O
due O
to O
mutation O
of O
a O
gene O
located O
in O
Xq28 O
that O
encodes O
a O
peroxisomal O
transporter O
protein O
of O
unknown O
function O
. O

The O
most O
common O
phenotype O
of O
ALD B
is O
the O
cerebral O
form O
( O
45 O
% O
) O
that O
develops O
in O
boys O
between O
5 O
- O
12 O
yr O
. O

Adrenomyeloneuropathy B
( O
AMN B
) O
involves O
the O
spinal O
cord O
and O
peripheral O
nerves O
in O
young O
adults O
( O
35 O
% O
) O
. O

Adrenal B
insufficiency I
( O
Addisons B
disease I
) O
is O
frequently O
associated O
with O
AMN B
or O
cerebral B
ALD I
and O
may O
remain O
the O
only O
clinical O
expression O
of O
ALD B
( O
8 O
% O
of O
cases O
) O
. O

The O
prevalence O
of O
ALD B
among O
adults O
with O
Addisons B
disease I
remains O
unknown O
. O

To O
evaluate O
this O
prevalence O
, O
we O
performed O
biochemical O
analysis O
of O
very O
long O
chain O
fatty O
acids O
in O
14 O
male O
patients O
( O
age O
ranging O
from O
12 O
- O
45 O
yr O
at O
diagnosis O
) O
previously O
diagnosed O
as O
having O
primary O
idiopathic O
adrenocortical B
insufficiency I
. O

By O
electrophysiological O
tests O
and O
magnetic O
resonance O
imaging O
it O
was O
determined O
that O
two O
patients O
had O
cerebral B
ALD I
, O
one O
had O
adrenomyeloneuropathy B
with O
cerebral O
involvement O
, O
and O
two O
had O
preclinical O
AMN B
. O

Our O
data O
support O
the O
hypothesis O
that O
ALD B
is O
a O
frequent O
cause O
of O
idiopathic O
Addisons B
disease I
in O
children O
and O
adults O
. O
. O

Tumor B
suppression O
and O
apoptosis O
of O
human O
prostate O
carcinoma O
mediated O
by O
a O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
. O

Prostate B
cancer I
is O
the O
second O
leading O
cause O
of O
male O
cancer B
deaths O
in O
the O
United O
States O
. O

Low O
incidence O
of O
BRCA2 O
mutations O
in O
breast O
carcinoma O
and O
other O
cancers B
. O

Inherited O
mutant O
alleles O
of O
familial O
tumour B
suppressor O
genes O
predispose O
individuals O
to O
particular O
types O
of O
cancer B
. O

In O
addition O
to O
an O
involvement O
in O
inherited O
susceptibility O
to O
cancer B
, O
these O
tumour B
suppressor O
genes O
are O
targets O
for O
somatic O
mutations O
in O
sporadic B
cancers I
of O
the O
same O
type O
found O
in O
the O
familial O
forms O
. O

An O
exception O
is O
BRCA1 O
, O
which O
contributes O
to O
a O
significant O
fraction O
of O
familial B
breast I
and I
ovarian I
cancer I
, O
but O
undergoes O
mutation O
at O
very O
low O
rates O
in O
sporadic B
breast I
and I
ovarian I
cancers I
. O

A O
second O
, O
recently O
identified O
familial B
breast I
cancer I
gene O
, O
BRCA2 O
( O
refs O
5 O
- O
8 O
) O
, O
accounts O
for O
a O
proportion O
of O
breast B
cancer I
roughly O
equal O
to O
BRCA1 O
. O

Like O
BRCA1 O
, O
BRCA2 O
behaves O
as O
a O
dominantly O
inherited O
tumour B
suppressor O
gene O
. O

Individuals O
who O
inherit O
one O
mutant O
allele O
are O
at O
increased O
risk O
for O
breast B
cancer I
, O
and O
the O
tumours B
they O
develop O
lose O
the O
wild O
- O
type O
allele O
by O
heterozygous O
deletion O
. O

Here O
we O
investigate O
the O
rate O
of O
BRCA2 O
mutation O
in O
sporadic O
breast O
cancers O
and O
in O
a O
set O
of O
cell O
lines O
that O
represent O
twelve O
other O
tumour B
types O
. O

Surprisingly O
, O
mutations O
in O
BRCA2 O
are O
infrequent O
in O
cancers B
including O
breast O
carcinoma O
. O

Founding O
BRCA1 O
mutations O
in O
hereditary B
breast I
and I
ovarian I
cancer I
in O
southern O
Sweden O
. O

Nine O
different O
germ O
- O
line O
mutations O
in O
the O
BRCA1 O
breast B
and I
ovarian I
cancer I
susceptibility O
gene O
were O
identified O
in O
15 O
of O
47 O
kindreds O
from O
southern O
Sweden O
, O
by O
use O
of O
SSCP O
and O
heteroduplex O
analysis O
of O
all O
exons O
and O
flanking O
intron O
region O
and O
by O
a O
protein O
- O
truncation O
test O
for O
exon O
11 O
, O
followed O
by O
direct O
sequencing O
. O

Eleven O
of O
the O
15 O
kindreds O
manifesting O
BRCA1 O
mutations O
were O
breast B
- I
ovarian I
cancer I
families O
, O
several O
of O
them O
with O
a O
predominant O
ovarian B
cancer I
phenotype O
. O

The O
set O
of O
32 O
families O
in O
which O
no O
BRCA1 O
alterations O
were O
detected O
included O
1 O
breast B
- I
ovarian I
cancer I
kindred O
manifesting O
clear O
linkage O
to O
the O
BRCA1 O
region O
and O
loss O
of O
the O
wild O
- O
type O
chromosome O
in O
associated O
tumors B
. O

Other O
tumor B
types O
found O
in O
BRCA1 O
mutation O
/ O
haplotype O
carriers O
included O
prostatic O
, O
pancreas O
, O
skin O
, O
and O
lung O
cancer O
, O
a O
malignant B
melanoma I
, O
an O
oligodendroglioma O
, O
and O
a O
carcinosarcoma O
. O

In O
all O
, O
12 O
of O
16 O
kindreds O
manifesting O
BRCA1 O
mutation O
or O
linkage O
contained O
ovarian B
cancer I
, O
as O
compared O
with O
only O
6 O
of O
the O
remaining O
31 O
families O
( O
P O
< O
. O
001 O
) O
. O

The O
present O
study O
confirms O
the O
involvement O
of O
BRCA1 O
in O
disease O
predisposition O
for O
a O
subset O
of O
hereditary B
breast I
cancer I
families O
often O
characterized O
by O
ovarian B
cancers I
. O

UKCCCR O
Familial O
Ovarian B
Cancer I
Study O
Group O
. O

Germ O
- O
line O
mutations O
of O
the O
BRCA1 O
gene O
are O
responsible O
for O
a O
substantial O
proportion O
of O
families O
with O
multiple O
cases O
of O
early O
- O
onset O
breast B
and I
/ I
or I
ovarian I
cancer I
. O

We O
have O
developed O
a O
multiplex O
heteroduplex O
analysis O
that O
is O
designed O
to O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
in O
a O
single O
- O
step O
screening O
procedure O
and O
that O
will O
detect O
approximately O
50 O
% O
of O
all O
BRCA1 O
mutations O
so O
far O
reported O
in O
breast B
/ I
ovarian I
cancer I
families O
. O

We O
have O
used O
this O
technique O
to O
analyze O
BRCA1 O
in O
162 O
families O
with O
a O
history O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
and O
identified O
12 O
distinct O
mutations O
in O
35 O
families O
. O
. O

A O
previously O
undescribed O
mutation O
within O
the O
tetramerisation O
domain O
of O
TP53 O
in O
a O
family O
with O
Li B
- I
Fraumeni I
syndrome I
. O

We O
report O
details O
of O
a O
family O
with O
classic O
Li B
- I
Fraumeni I
syndrome I
in O
which O
there O
is O
a O
mutation O
in O
codon O
344 O
of O
the O
tumour B
suppressor O
gene O
TP53 O
. O

This O
is O
the O
first O
report O
of O
a O
mutation O
at O
this O
residue O
in O
either O
sporadic B
tumours I
or O
in O
the O
germline O
and O
the O
first O
report O
of O
a O
germline O
mutation O
within O
the O
tetramerisation O
domain O
. O

The O
family O
does O
not O
appear O
to O
be O
remarkable O
in O
the O
spectrum O
of O
tumours B
, O
and O
there O
is O
loss O
of O
the O
wild O
- O
type O
allele O
in O
a O
leiomyosarcoma O
from O
the O
proband O
. O

A O
cell O
line O
has O
been O
established O
from O
the O
tumour B
of O
the O
proband O
and O
cytogenetic O
and O
molecular O
studies O
carried O
out O
, O
providing O
an O
extensive O
analysis O
in O
this O
family O
. O
. O

The O
spectrum O
of O
RB1 O
germ O
- O
line O
mutations O
in O
hereditary B
retinoblastoma I
. O

We O
have O
searched O
for O
germ O
- O
line O
RB1 O
mutations O
in O
119 O
patients O
with O
hereditary B
retinoblastoma I
. O

No O
correlation O
between O
the O
location O
of O
frameshift O
or O
nonsense O
mutations O
and O
phenotypic O
features O
, O
including O
age O
at O
diagnosis O
, O
the O
number O
of O
tumor B
foci O
, O
and O
manifestation O
of O
nonocular O
tumors O
was O
observed O
. O
. O

Phenotypic O
characterization O
of O
individuals O
with O
30 O
- O
40 O
CAG O
repeats O
in O
the O
Huntington B
disease I
( O
HD B
) O
gene O
reveals O
HD B
cases O
with O
36 O
repeats O
and O
apparently O
normal O
elderly O
individuals O
with O
36 O
- O
39 O
repeats O
. O

Abnormal O
CAG O
expansions O
in O
the O
IT O
- O
15 O
gene O
are O
associated O
with O
Huntington B
disease I
( O
HD B
) O
. O

In O
the O
diagnostic O
setting O
it O
is O
necessary O
to O
define O
the O
limits O
of O
the O
CAG O
size O
ranges O
on O
normal O
and O
HD B
- O
associated O
chromosomes O
. O

Seven O
HD B
patients O
had O
36 O
repeats O
, O
which O
confirms O
that O
this O
allele O
is O
associated O
with O
disease O
. O

Individuals O
without O
apparent O
symptoms O
or O
signs O
of O
HD B
were O
found O
at O
36 O
repeats O
( O
aged O
74 O
, O
78 O
, O
79 O
, O
and O
87 O
years O
) O
, O
37 O
repeats O
( O
aged O
69 O
years O
) O
, O
38 O
repeats O
( O
aged O
69 O
and O
90 O
years O
) O
, O
and O
39 O
repeats O
( O
aged O
67 O
, O
90 O
, O
and O
95 O
years O
) O
. O

The O
detailed O
case O
histories O
of O
an O
exceptional O
case O
from O
this O
series O
will O
be O
presented O
a O
95 O
- O
year O
- O
old O
man O
with O
39 O
repeats O
who O
did O
not O
have O
classical O
features O
of O
HD B
. O

The O
apparently O
healthy O
survival O
into O
old O
age O
of O
some O
individuals O
with O
36 O
- O
39 O
repeats O
suggests O
that O
the O
HD B
mutation O
may O
not O
always O
be O
fully O
penetrant O
. O
. O

Identification O
and O
expression O
of O
eight O
novel O
mutations O
among O
non O
- O
Jewish O
patients O
with O
Canavan B
disease I
. O

Canavan B
disease I
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
that O
is O
caused O
by O
the O
deficiency B
of I
aspartoacylase I
( O
ASPA O
) O
. O

The O
majority O
of O
patients O
with O
Canavan B
disease I
are O
from O
an O
Ashkenazi O
Jewish O
background O
. O

The O
current O
study O
was O
aimed O
at O
finding O
the O
molecular O
basis O
of O
Canavan B
disease I
in O
25 O
independent O
patients O
of O
non O
- O
Jewish O
background O
. O

The O
homozygous O
32 O
deltaT O
deletion O
was O
identified O
in O
the O
only O
known O
patient O
of O
African O
- O
American O
origin O
with O
Canavan B
disease I
. O

In O
vitro O
expression O
of O
mutant O
cDNA O
clones O
demonstrated O
that O
all O
of O
these O
mutations O
led O
to O
a O
deficiency O
of O
ASPA O
and O
should O
therefore O
result O
in O
Canavan B
disease I
. O
. O

Identification O
and O
chromosomal O
localization O
of O
Atm O
, O
the O
mouse O
homolog O
of O
the O
ataxia B
- I
telangiectasia I
gene O
. O

Atm O
, O
the O
mouse O
homolog O
of O
the O
human O
ATM O
gene O
defective O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
has O
been O
identified O
. O

The O
mouse O
homolog O
of O
the O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
gene O
is O
highly O
conserved O
and O
maps O
near O
the O
scurfy O
( O
sf O
) O
mutation O
on O
the O
X O
chromosome O
. O

The O
mouse O
WASP O
gene O
, O
the O
homolog O
of O
the O
gene O
mutated O
in O
Wiskott B
- I
Aldrich I
syndrome I
, O
has O
been O
isolated O
and O
sequenced O
. O
the O
predicted O
amino O
acid O
sequence O
is O
86 O
% O
identical O
to O
the O
human O
WASP O
sequence O
. O

This O
localization O
makes O
Wasp O
a O
candidate O
for O
involvement O
in O
scurfy O
, O
a O
T O
cell O
- O
mediated O
fatal O
lymphoreticular O
disease O
of O
mice O
that O
has O
previously O
been O
proposed O
as O
a O
mouse O
homolog O
of O
Wiskott B
- I
Aldrich I
syndrome I
. O

Colchicine O
in O
breast O
milk O
of O
patients O
with O
familial B
Mediterranean I
fever I
. O

To O
clarify O
whether O
colchicine O
is O
excreted O
in O
breast O
milk O
, O
and O
to O
compare O
its O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
lactating O
women O
who O
have O
familial B
Mediterranean I
fever I
( O
FMF B
) O
. O

The O
study O
evaluated O
4 O
patients O
with O
FMF B
who O
had O
been O
taking O
colchicine O
on O
a O
long O
- O
term O
basis O
. O

Furthermore O
, O
based O
on O
our O
clinical O
experience O
, O
nursing O
appears O
to O
be O
safe O
for O
lactating O
women O
with O
FMF B
who O
continue O
to O
take O
colchicine O
. O

Abnormal O
myotonic B
dystrophy I
protein O
kinase O
levels O
produce O
only O
mild O
myopathy B
in O
mice O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
commonly O
associated O
with O
CTG O
repeat O
expansions O
within O
the O
gene O
for O
DM O
- O
protein O
kinase O
( O
DMPK O
) O
. O

Nullizygous O
( O
- O
/ O
- O
) O
mice O
showed O
only O
inconsistent O
and O
minor O
size O
changes O
in O
head O
and O
neck O
muscle O
fibres O
at O
older O
age O
, O
animals O
with O
the O
highest O
DMPK O
transgene O
expression O
showed O
hypertrophic B
cardiomyopathy I
and O
enhanced O
neonatal O
mortality O
. O

However O
, O
both O
models O
lack O
other O
frequent O
DM B
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy O
, O
myotonia B
, O
cataract B
and O
male O
- O
infertility O
. O

Mice O
lacking O
the O
myotonic B
dystrophy I
protein O
kinase O
develop O
a O
late O
onset O
progressive O
myopathy B
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
an O
autosomal B
dominant I
disorder I
resulting O
from O
the O
expansion O
of O
a O
CTG O
repeat O
in O
the O
3 O
untranslated O
region O
of O
a O
putative O
protein O
kinase O
( O
DMPK O
) O
. O

To O
elucidate O
the O
role O
of O
DMPK O
in O
DM B
pathogenesis O
we O
have O
developed O
Dmpk O
deficient O
( O
Dmpk O
- O
/ O
- O
) O
mice O
. O

Dmpk O
- O
/ O
- O
mice O
develop O
a O
late O
- O
onset O
, O
progressive O
skeletal O
myopathy O
that O
shares O
some O
pathological O
features O
with O
DM B
. O

Our O
results O
indicate O
that O
DMPK O
may O
be O
necessary O
for O
the O
maintenance O
of O
skeletal O
muscle O
structure O
and O
function O
and O
suggest O
that O
a O
decrease O
in O
DMPK O
levels O
may O
contribute O
to O
DM B
pathology O
. O
. O

The O
tumor B
suppressor O
gene O
Brca1 O
is O
required O
for O
embryonic O
cellular O
proliferation O
in O
the O
mouse O
. O

Mutations O
of O
the O
BRCA1 O
gone O
in O
humans O
are O
associated O
with O
predisposition O
to O
breast B
and I
ovarian I
cancers I
. O

We O
show O
here O
that O
Brca1 O
+ O
/ O
- O
mice O
are O
normal O
and O
fertile O
and O
lack O
tumors B
by O
age O
eleven O
months O
. O

Increased O
coronary B
heart I
disease I
in O
Japanese O
- O
American O
men O
with O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
despite O
increased O
HDL O
levels O
. O

Plasma O
high O
density O
lipoprotein O
( O
HDL O
) O
levels O
are O
strongly O
genetically O
determined O
and O
show O
a O
general O
inverse O
relationship O
with O
coronary B
heart I
disease I
( O
CHD O
) O
. O

Thus O
, O
genetic O
CETP B
deficiency I
appears O
to O
be O
an O
independent O
risk O
factor O
for O
CHD O
, O
primarily O
due O
to O
increased O
CHD O
prevalence O
in O
men O
with O
the O
D442G O
mutation O
and O
HDL O
cholesterol O
between O
41 O
and O
60 O
mg O
/ O
dl O
. O

The O
Rb1 O
gene O
has O
been O
implicated O
with O
retinoblastoma B
and O
is O
located O
on O
human O
Chromosome O
( O
Chr O
) O
13q14 O
. O

Wiskott B
- I
Aldrich I
syndrome I
: O
no O
strict O
genotype O
- O
phenotype O
correlations O
but O
clustering O
of O
missense O
mutations O
in O
the O
amino O
- O
terminal O
part O
of O
the O
WASP O
gene O
product O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
gene O
was O
found O
to O
be O
mutated O
in O
patients O
presenting O
with O
WAS B
and O
in O
patients O
showing O
X B
- I
linked I
thrombocytopenia I
. O

No O
genotype O
- O
phenotype O
correlation O
emerged O
after O
a O
comparison O
of O
the O
identified O
mutations O
with O
the O
resulting O
clinical O
picture O
for O
a O
classical O
WAS B
phenotype O
. O

Aniridia B
in O
man O
and O
Small O
eye O
in O
mice O
are O
semidominant O
developmental O
disorders O
caused O
by O
mutations O
within O
the O
paired O
box O
gene O
PAX6 O
. O

Whereas O
heterozygotes O
suffer O
from O
iris B
hypoplasia I
, O
homozygous O
mice O
lack O
eyes O
and O
nasal O
cavities O
and O
exhibit O
brain O
abnormalities O
. O

This O
question O
is O
of O
particular O
interest O
for O
the O
human O
enzyme O
galactose O
- O
l O
- O
phosphate O
uridylyl O
- O
transferase O
( O
GALT O
) O
, O
impairment O
of O
which O
results O
in O
the O
inherited O
metabolic O
disorder O
galactosemia B
, O
because O
many O
if O
not O
most O
patients O
studied O
to O
date O
are O
compound O
heterozygotes O
rather O
than O
true O
molecular O
homozygotes O
. O

These O
results O
are O
significant O
not O
only O
in O
terms O
of O
their O
implications O
for O
furthering O
our O
understanding O
of O
galactosemia B
and O
GALT O
holoenzyme O
structure O
- O
function O
relationships O
but O
also O
because O
the O
system O
described O
may O
serve O
as O
a O
model O
for O
similar O
studies O
of O
other O
complexes O
composed O
of O
multiple O
subunits O
. O
. O

Apoptosis O
has O
recently O
been O
recognized O
as O
a O
mode O
of O
cell O
death O
in O
Huntington B
disease I
( O
HD B
) O
. O

Here O
we O
show O
that O
apoptotic O
extracts O
and O
apopain O
itself O
specifically O
cleave O
the O
HD B
gene O
product O
, O
huntingtin O
. O

Our O
results O
show O
that O
huntingtin O
is O
cleaved O
by O
cysteine O
proteases O
and O
suggest O
that O
HD B
might O
be O
a O
disorder O
of O
inappropriate O
apoptosis O
. O
. O

To O
begin O
to O
address O
the O
hypothesis O
that O
abnormal O
regulation O
of O
the O
breast B
/ I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
is O
a O
critical O
step O
in O
sporadic O
breast O
/ O
ovarian O
tumorigenesis O
, O
we O
have O
determined O
the O
detailed O
structure O
of O
the O
BRCA1 O
genomic O
region O
. O

Deletion O
of O
small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
in O
Prader B
- I
Willi I
syndrome I
detected O
by O
fluorescence O
in O
situ O
hybridization O
: O
two O
sibs O
with O
the O
typical O
phenotype O
without O
a O
cytogenetic O
deletion O
in O
chromosome O
15q O
. O

The O
small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
gene O
is O
regarded O
as O
one O
of O
the O
candidates O
for O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

We O
describe O
two O
sibs O
with O
typical O
PWS B
presenting O
deletion O
of O
SNRPN O
detected O
by O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
. O

This O
implies O
a O
smaller O
deletion O
limited O
to O
the O
PWS B
critical O
region O
. O

FISH O
with O
a O
SNRPN O
probe O
will O
permit O
analysis O
of O
PWS B
patients O
with O
limited O
deletions O
not O
detectable O
with O
other O
probes O
. O
. O

The O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
product O
is O
thought O
to O
down O
- O
regulate O
transcription O
by O
antagonizing O
elongin O
- O
enhanced O
transcriptional O
elongation O
. O

Germline O
VHL B
gene O
mutations O
predispose O
to O
the O
development O
of O
retinal O
, O
cerebellar O
and O
spinal O
haemangioblastomas O
, O
renal B
cell I
carcinoma I
and O
phaeochromocytoma O
. O

In O
addition O
, O
somatic O
Inactivation O
of O
the O
VHL B
gene O
is O
frequent O
in O
sporadic B
renal I
cell I
carcinoma I
and O
haemangioblastoma O
. O

Regulation O
of O
transcript O
elongation O
is O
an O
important O
control O
mechanism O
for O
gene O
expression O
and O
the O
VHL B
gene O
might O
modify O
the O
expression O
of O
proto O
- O
oncogenes O
and O
growth O
suppressor O
genes O
during O
embryogenesis O
. O

We O
therefore O
investigated O
the O
expression O
of O
VHL B
mRNA O
during O
human O
embryogenesis O
by O
in O
situ O
hybridization O
studies O
at O
4 O
, O
6 O
and O
10 O
weeks O
post O
conception O
. O

Although O
VHL B
mRNA O
was O
expressed O
in O
all O
three O
germ O
layers O
, O
strong O
expression O
was O
noted O
in O
the O
central O
nervous O
system O
, O
kidneys O
, O
testis O
and O
lung O
. O

Within O
the O
kidney O
, O
VHL B
mRNA O
was O
differentially O
expressed O
within O
renal O
tubules O
suggesting O
that O
the O
VHL B
gene O
product O
may O
have O
a O
specific O
role O
in O
kidney O
development O
. O

Two O
alternatively O
spliced O
VHL B
mRNAs O
characterized O
by O
inclusion O
( O
isoform O
I O
) O
or O
exclusion O
( O
isoform O
II O
) O
of O
exon O
2 O
are O
transcribed O
in O
adult O
tissues O
. O

To O
investigate O
if O
the O
two O
isoforms O
are O
differentially O
expressed O
during O
embryogenesis O
, O
VHL B
mRNA O
was O
reverse O
transcribed O
from O
13 O
fetal O
tissues O
( O
8 O
- O
10 O
weeks O
gestation O
) O
. O

The O
quantitative O
distribution O
of O
VHL B
mRNA O
within O
fetal O
tissues O
reflected O
that O
seen O
by O
in O
situ O
hybridization O
and O
the O
ratio O
of O
the O
two O
VHL B
isoforms O
was O
similar O
between O
tissues O
. O

Although O
the O
genes O
regulated O
by O
the O
VHL B
gene O
product O
have O
not O
yet O
been O
identified O
, O
our O
findings O
are O
compatible O
with O
the O
hypothesis O
that O
VHL B
- O
mediated O
control O
of O
transcriptional O
elongation O
may O
have O
a O
role O
in O
normal O
human O
development O
. O
. O

Genetic O
heterogeneity O
in O
hereditary B
breast I
cancer I
: O
role O
of O
BRCA1 O
and O
BRCA2 O
. O

The O
common O
hereditary O
forms O
of O
breast B
cancer I
have O
been O
largely O
attributed O
to O
the O
inheritance O
of O
mutations O
in O
the O
BRCA1 O
or O
BRCA2 O
genes O
. O

However O
, O
it O
is O
not O
yet O
clear O
what O
proportion O
of O
hereditary B
breast I
cancer I
is O
explained O
by O
BRCA1 O
and O
BRCA2 O
or O
by O
some O
other O
unidentified O
susceptibility O
gene O
( O
s O
) O
. O

We O
describe O
the O
proportion O
of O
hereditary B
breast I
cancer I
explained O
by O
BRCA1 O
or O
BRCA2 O
in O
a O
sample O
of O
North O
American O
hereditary O
breast O
cancers O
and O
assess O
the O
evidence O
for O
additional O
susceptibility O
genes O
that O
may O
confer O
hereditary B
breast I
or I
ovarian I
cancer I
risk O
. O

Twenty O
- O
three O
families O
were O
identified O
through O
two O
high O
- O
risk O
breast B
cancer I
research O
programs O
. O

Genetic O
analysis O
was O
undertaken O
to O
establish O
linkage O
between O
the O
breast B
or I
ovarian I
cancer I
cases O
and O
markers O
on O
chromosomes O
17q O
( O
BRCA1 O
) O
and O
13q O
( O
BRCA2 O
) O
. O

BRCA1 O
and O
BRCA2 O
probably O
explain O
the O
majority O
of O
hereditary B
breast I
cancer I
that O
exists O
in O
the O
North O
American O
population O
. O

However O
, O
one O
or O
more O
additional O
genes O
may O
yet O
be O
found O
that O
explain O
some O
proportion O
of O
hereditary B
breast I
cancer I
. O
. O

An O
intronic O
mutation O
in O
a O
lariat O
branchpoint O
sequence O
is O
a O
direct O
cause O
of O
an O
inherited O
human O
disorder O
( O
fish B
- I
eye I
disease I
) O
. O

Three O
sisters O
were O
shown O
to O
suffer O
from O
fish B
- I
eye I
disease I
( O
FED O
) O
, O
a O
disorder O
which O
is O
caused O
by O
mutations O
in O
the O
gene O
coding O
for O
lecithin O
cholesterol O
acyltransferase O
( O
LCAT O
) O
. O

Mutations O
associated O
with O
variant O
phenotypes O
in O
ataxia B
- I
telangiectasia I
. O

We O
have O
identified O
14 O
families O
with O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
in O
which O
mutation O
of O
the O
ATM O
gene O
is O
associated O
with O
a O
less O
severe O
clinical O
and O
cellular O
phenotype O
( O
approximately O
10 O
% O
- O
15 O
% O
of O
A B
- I
T I
families O
identified O
in O
the O
United O
Kingdom O
) O
. O

The O
second O
A B
- I
T I
allele O
has O
a O
different O
mutation O
in O
each O
patient O
. O

Mutations O
detected O
in O
two O
of O
four O
of O
these O
are O
missense O
mutations O
, O
normally O
rare O
in O
A B
- I
T I
patients O
. O

The O
demonstration O
of O
mutations O
giving O
rise O
to O
a O
slightly O
milder O
phenotype O
in O
A B
- I
T I
raises O
the O
interesting O
question O
of O
what O
range O
of O
phenotypes O
might O
occur O
in O
individuals O
in O
whom O
both O
mutations O
are O
milder O
. O

To O
define O
the O
possible O
role O
of O
the O
VHL B
gene O
in O
the O
development O
of O
sporadic B
renal I
cell I
carcinomas I
, O
91 O
different O
parenchymal O
tumours O
of O
the O
kidney O
have O
been O
investigated O
for O
mutation O
of O
the O
VHL B
gene O
by O
single O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
and O
/ O
or O
heteroduplex O
( O
HD O
) O
techniques O
. O

Chromosome O
3p O
deletion O
was O
detected O
in O
98 O
per O
cent O
of O
non O
- O
papillary O
renal O
cell O
carcinomas O
and O
in O
25 O
per O
cent O
of O
chromophobe O
renal B
cell I
carcinomas I
. O

No O
mobility O
shift O
was O
seen O
in O
any O
of O
the O
23 O
chromophobe O
renal B
cell I
carcinomas I
. O

In O
addition O
, O
15 O
papillary O
renal O
cell O
tumours O
and O
ten O
renal O
oncocytomas O
, O
which O
are O
characterized O
by O
genetic O
changes O
other O
than O
loss O
of O
chromosome O
3p O
sequences O
, O
were O
analysed O
for O
mutation O
of O
the O
VHL B
gene O
. O

None O
of O
these O
tumours B
showed O
abnormal O
migration O
patterns O
. O

The O
results O
indicate O
that O
mutation O
of O
the O
VHL B
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non O
- O
papillary O
renal O
cell O
carcinoma O
. O
. O

The O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
protein O
, O
emerin O
, O
is O
a O
nuclear O
membrane O
protein O
. O

A O
muscle O
biopsy O
from O
an O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
( O
EMDM O
) O
patient O
showed O
complete O
absence O
of O
emerin O
by O
both O
Western O
blotting O
and O
immunohistochemistry O
, O
suggesting O
a O
simple O
diagnostic O
antibody O
test O
for O
EDMD B
families O
. O

Mutation O
of O
MSH3 O
in O
endometrial B
cancer I
and O
evidence O
for O
its O
functional O
role O
in O
heteroduplex O
repair O
. O

Many O
human O
tumours B
have O
length O
alterations O
in O
repetitive O
sequence O
elements O
. O

Although O
this O
microsatellite O
instability O
has O
been O
attributed O
to O
mutations O
in O
four O
DNA O
mismatch O
repair O
genes O
in O
hereditary B
nonpolyposis I
colorectal I
cancer I
( O
HNPCC B
) O
kindreds O
, O
many O
sporadic B
tumours I
exhibit O
instability O
but O
no O
detectable O
mutations O
in O
these O
genes O
. O

Together O
the O
data O
suggest O
that O
the O
MSH3 O
gene O
encodes O
a O
product O
that O
functions O
in O
repair O
of O
some O
but O
not O
all O
pre O
- O
mutational O
intermediates O
, O
its O
mutation O
in O
tumours B
can O
result O
in O
genomic O
instability O
and O
, O
as O
in O
yeast O
, O
MSH3 O
and O
MSH6 O
are O
partially O
redundant O
for O
mismatch O
repair O
. O
. O

Comparative O
genome O
mapping O
of O
the O
ataxia B
- I
telangiectasia I
region O
in O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
. O

Chromosomal O
locations O
of O
the O
Atm O
( O
ataxia B
- I
telangiectasia I
( O
AT B
) O
- O
mutated O
) O
and O
Acat1 O
( O
mitochondrial O
acetoacetyl O
- O
CoA O
thiolase O
) O
genes O
in O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
were O
determined O
by O
direct O
R O
- O
banding O
FISH O
. O

Fine O
genetic O
linkage O
mapping O
of O
the O
mouse O
AT B
region O
was O
performed O
using O
the O
interspecific O
backcross O
mice O
. O

An O
animal O
model O
for O
Norrie B
disease I
( O
ND B
) O
: O
gene O
targeting O
of O
the O
mouse O
ND B
gene O
. O

In O
order O
to O
elucidate O
the O
cellular O
and O
molecular O
processes O
which O
are O
involved O
in O
Norrie B
disease I
( O
ND B
) O
, O
we O
have O
used O
gene O
targeting O
technology O
to O
generate O
ND B
mutant O
mice O
. O

The O
murine O
homologue O
of O
the O
ND B
gene O
was O
cloned O
and O
shown O
to O
encode O
a O
polypeptide O
that O
shares O
94 O
% O
of O
the O
amino O
acid O
sequence O
with O
its O
human O
counterpart O
. O

Hemizygous O
mice O
carrying O
a O
replacement O
mutation O
in O
exon O
2 O
of O
the O
ND B
gene O
developed O
retrolental O
structures O
in O
the O
vitreous O
body O
and O
showed O
an O
overall O
disorganization O
of O
the O
retinal O
ganglion O
cell O
layer O
. O

These O
ocular O
findings O
are O
consistent O
with O
observations O
in O
ND B
patients O
and O
the O
generated O
mouse O
line O
provides O
a O
faithful O
model O
for O
study O
of O
early O
pathogenic O
events O
in O
this O
severe O
X O
- O
linked O
recessive O
neurological O
disorder O
. O
. O

The O
hybrid O
PAX3 O
- O
FKHR O
fusion O
protein O
of O
alveolar B
rhabdomyosarcoma I
transforms O
fibroblasts O
in O
culture O
. O

Somatic O
- O
cell O
selection O
is O
a O
major O
determinant O
of O
the O
blood O
- O
cell O
phenotype O
in O
heterozygotes O
for O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
mutations O
causing O
severe O
enzyme B
deficiency I
. O

In O
most O
people O
with O
red O
- O
blood O
- O
cell O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
, O
the O
enzyme O
- O
deficient O
phenotype O
is O
only O
moderately O
expressed O
in O
nucleated O
cells O
. O

However O
, O
in O
a O
small O
subset O
of O
hemizygous O
males O
who O
suffer O
from O
chronic B
nonspherocytic I
hemolytic I
anemia I
, O
the O
underlying O
mutations O
( O
designated O
class O
I O
) O
cause O
more O
- O
severe O
G6PD B
deficiency I
, O
and O
this O
might O
provide O
an O
opportunity O
for O
selection O
in O
heterozygous O
females O
during O
development O
. O

Thus O
, O
it O
appears O
that O
severe O
G6PD B
deficiency I
affects O
adversely O
the O
proliferation O
or O
the O
survival O
of O
nucleated O
blood O
cells O
and O
that O
this O
phenotypic O
characteristic O
is O
critical O
during O
hematopoiesis O
. O
. O

Analysis O
of O
meiotic O
segregation O
, O
using O
single O
- O
sperm O
typing O
: O
meiotic O
drive O
at O
the O
myotonic B
dystrophy I
locus O
. O

Meiotic O
drive O
at O
the O
myotonic B
dystrophy I
( O
DM B
) O
locus O
has O
recently O
been O
suggested O
as O
being O
responsible O
for O
maintaining O
the O
frequency O
, O
in O
the O
human O
population O
, O
of O
DM B
chromosomes O
capable O
of O
expansion O
to O
the O
disease O
state O
. O

In O
order O
to O
test O
this O
hypothesis O
, O
we O
have O
studied O
samples O
of O
single O
sperm O
from O
three O
individuals O
heterozygous O
at O
the O
DM B
locus O
, O
each O
with O
one O
allele O
larger O
and O
one O
allele O
smaller O
than O
19 O
CTG O
repeats O
. O

To O
guard O
against O
the O
possible O
problem O
of O
differential O
PCR O
amplification O
rates O
based O
on O
the O
lengths O
of O
the O
alleles O
, O
the O
sperm O
were O
also O
typed O
at O
another O
closely O
linked O
marker O
whose O
allele O
size O
was O
unrelated O
to O
the O
allele O
size O
at O
the O
DM B
locus O
. O

This O
suggests O
that O
any O
greater O
amount O
of O
segregation O
distortion O
at O
the O
myotonic B
dystrophy I
locus O
must O
result O
from O
events O
following O
sperm O
ejaculation O
. O

LPP O
, O
the O
preferred O
fusion O
partner O
gene O
of O
HMGIC O
in O
lipomas B
, O
is O
a O
novel O
member O
of O
the O
LIM O
protein O
gene O
family O
. O

A O
major O
cytogenetic O
subgroup O
of O
lipomas B
is O
characterized O
by O
recurrent O
chromosome O
aberrations O
, O
mainly O
translocations O
, O
that O
involve O
chromosome O
segment O
12q13 O
- O
q15 O
. O

Absence O
of O
disease O
phenotype O
and O
intergenerational O
stability O
of O
the O
CAG O
repeat O
in O
transgenic O
mice O
expressing O
the O
human O
Huntington B
disease I
transcript O
. O

The O
mutation O
underlying O
Huntington B
disease I
( O
HD B
) O
is O
CAG O
expansion O
in O
the O
first O
exon O
of O
the O
HD B
gene O
. O

In O
order O
to O
investigate O
the O
role O
of O
CAG O
expansion O
in O
the O
pathogenesis O
of O
HD B
, O
we O
have O
produced O
transgenic O
mice O
containing O
the O
full O
length O
human O
HD B
cDNA O
with O
44 O
CAG O
repeats O
. O

Despite O
high O
levels O
of O
mRNA O
expression O
, O
there O
was O
no O
evidence O
of O
the O
HD B
gene O
product O
in O
any O
of O
these O
transgenic O
mice O
. O

In O
vitro O
transfection O
studies O
indicated O
that O
the O
inclusion O
of O
120 O
bp O
of O
the O
5 O
UTR O
in O
the O
cDNA O
construct O
and O
the O
presence O
of O
a O
frameshift O
mutation O
at O
nucleotide O
2349 O
prevented O
expression O
of O
the O
HD B
cDNA O
. O

These O
findings O
suggest O
that O
the O
pathogenesis O
of O
HD B
is O
not O
mediated O
through O
DNA O
- O
protein O
interaction O
and O
that O
presence O
of O
the O
RNA O
transcript O
with O
an O
expanded O
CAG O
repeat O
is O
insufficient O
to O
cause O
the O
disease O
. O

Rather O
, O
translation O
of O
the O
CAG O
is O
crucial O
for O
the O
pathogenesis O
of O
HD B
. O

Fluorescence O
in O
situ O
hybridisation O
( O
FISH O
) O
studies O
with O
distal O
11p13 O
specific O
cosmids O
showed O
that O
the O
chromosome O
11 O
breakpoint O
lay O
between O
the O
aniridia B
( O
PAX6 O
) O
locus O
and O
a O
region O
approximately O
100 O
kb O
distal O
to O
PAX6 O
defined O
by O
the O
cosmid O
FO2121 O
. O

Although O
this O
patient O
did O
not O
have O
a O
detectable O
deletion O
within O
PAX6 O
, O
her O
aniridia B
may O
have O
resulted O
from O
a O
disruption O
of O
the O
distal O
chromatin O
domain O
containing O
either O
enhancers O
or O
regulators O
for O
PAX6 O
. O

This O
case O
may O
therefore O
be O
another O
example O
of O
aniridia B
caused O
by O
a O
position O
effect O
as O
recently O
described O
in O
two O
familial B
aniridia I
patients O
in O
which O
the O
phenotype O
cosegregated O
with O
chromosome O
abnormalities O
with O
11p13 O
breakpoints O
. O
. O

Muscle O
expression O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
deficiency I
in O
different O
variants O
. O

Muscle O
expression O
of O
G6PD B
deficiency I
has O
been O
investigated O
in O
Mediterranean O
, O
Seattle O
- O
like O
and O
A O
- O
variants O
. O

Gene O
therapy O
for O
phenylketonuria B
. O

Classical O
phenylketonuria B
( O
PKU B
) O
is O
an O
autosomal B
recessive I
disorder I
caused O
by O
a O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

Limitations O
of O
the O
current O
dietary O
treatment O
for O
PKU B
have O
led O
to O
the O
development O
of O
potential O
treatments O
based O
on O
somatic O
gene O
transfer O
. O

Vectors O
derived O
from O
a O
recombinant O
retrovirus O
or O
a O
DNA O
/ O
protein O
complex O
can O
efficiently O
transduce O
the O
PAH O
cDNA O
into O
PAH B
- I
deficient I
hepatocytes O
in O
vitro O
, O
but O
the O
application O
of O
these O
vector O
systems O
is O
presently O
limited O
by O
their O
low O
transduction O
efficiency O
in O
vivo O
. O

In O
contrast O
, O
a O
vector O
derived O
from O
a O
recombinant O
adenovirus O
can O
restore O
10 O
% O
- O
80 O
% O
of O
normal O
hepatic O
PAH O
activity O
into O
PAH B
- I
deficient I
mice O
, O
which O
completely O
normalizes O
serum O
phenylalanine O
levels O
. O

However O
, O
these O
findings O
suggest O
that O
PKU B
can O
be O
completely O
corrected O
by O
somatic O
gene O
therapy O
, O
and O
provide O
some O
direction O
for O
the O
future O
development O
of O
adenoviral O
vectors O
. O
. O

BRCA1 O
and O
BRCA2 O
are O
the O
two O
major O
identified O
causes O
of O
inherited B
breast I
cancer I
, O
with O
mutations O
in O
either O
gene O
conferring O
up O
to O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B
cancer I
in O
carrier O
females O
. O

Mutations O
in O
BRCA1 O
account O
for O
approximately O
45 O
% O
of O
familial B
breast I
cancer I
and O
90 O
% O
of O
inherited B
breast I
/ I
ovarian I
cancer I
, O
whereas O
mutations O
in O
BRCA2 O
account O
for O
a O
comparable O
percentage O
of O
inherited B
breast I
cancer I
cases O
. O

The O
6174delT O
mutation O
in O
BRCA2 O
was O
recently O
identified O
as O
a O
frequent O
mutation O
in O
8 O
out O
of O
107 O
Ashkenazi O
Jewish O
women O
diagnosed O
with O
breast B
cancer I
by O
age O
50 O
( O
ref O
. O
8 O
) O
, O
as O
well O
as O
in O
three O
Ashkenazi O
male B
breast I
cancer I
patients O
. O

We O
have O
conducted O
a O
large O
- O
scale O
population O
study O
to O
investigate O
the O
prevalence O
of O
specific O
BRCA1 O
and O
BRCA2 O
mutations O
in O
Ashkenazi O
Jewish O
individuals O
who O
were O
unselected O
for O
breast B
cancer I
. O

This O
expanded O
population O
- O
based O
study O
confirms O
that O
the O
BRCA1 O
185delAG O
mutation O
and O
the O
BRCA2 O
6174delT O
mutation O
constitute O
the O
two O
most O
frequent O
mutation O
alleles O
predisposing O
to O
hereditary B
breast I
cancer I
among O
the O
Ashkenazim O
, O
and O
suggests O
a O
relatively O
lower O
penetrance O
for O
the O
6174delT O
mutation O
in O
BRCA2 O

The O
gene O
mutated O
in O
ataxia B
- I
telangiectasia I
( O
AT B
) O
patients O
, O
denoted O
ATM O
, O
encodes O
a O
putative O
protein O
or O
lipid O
kinase O
. O

Consistent O
with O
cellular O
defects O
of O
AT B
patients O
, O
the O
ATM O
- O
/ O
- O
cells O
are O
hypersensitive O
to O
gamma O
- O
irradiation O
and O
defective O
in O
cell O
- O
cycle O
arrest O
following O
radiation O
, O
correlating O
with O
a O
defective O
up O
- O
regulation O
of O
p53 O
. O

ATM O
+ O
/ O
- O
fibroblasts O
and O
thymocytes O
showed O
intermediately O
defective O
responses O
to O
irradiation O
but O
no O
growth O
defect O
, O
suggesting O
that O
the O
increased O
cancer B
risk O
of O
AT B
heterozygotes O
could O
be O
attributable O
to O
poor O
checkpoint O
function O
. O
. O

Targeted O
disruption O
of O
ATM O
leads O
to O
growth B
retardation I
, O
chromosomal O
fragmentation O
during O
meiosis O
, O
immune B
defects I
, O
and O
thymic B
lymphoma I
. O

ATM O
, O
the O
gene O
mutated O
in O
the O
inherited O
human O
disease O
ataxia B
- I
telangiectasia I
, O
is O
a O
member O
of O
a O
family O
of O
kinases O
involved O
in O
DNA O
metabolism O
and O
cell O
- O
cycle O
checkpoint O
control O
. O

Initial O
evaluation O
of O
the O
ATM O
knockout O
animals O
indicates O
that O
inactivation O
of O
the O
mouse O
ATM O
gene O
recreates O
much O
of O
the O
phenotype O
of O
ataxia B
- I
telangiectasia I
. O

The O
infertility B
of O
ATM O
- O
/ O
- O
mice O
results O
from O
meiotic O
failure O
. O

Immune B
defects I
also O
are O
evident O
in O
ATM O
- O
/ O
- O
mice O
, O
including O
reduced O
numbers O
of O
B220 O
+ O
CD43 O
- O
pre O
- O
B O
cells O
, O
thymocytes O
, O
and O
peripheral O
T O
cells O
, O
as O
well O
as O
functional O
impairment O
of O
T O
- O
cell O
- O
dependent O
immune O
responses O
. O

These O
findings O
indicate O
that O
the O
ATM O
gene O
product O
plays O
an O
essential O
role O
in O
a O
diverse O
group O
of O
cellular O
processes O
, O
including O
meiosis O
, O
the O
normal O
growth O
of O
somatic O
tissues O
, O
immune O
development O
, O
and O
tumor B
suppression O
. O
. O

This O
agrees O
well O
with O
the O
fact O
that O
cardiac O
and O
muscle O
symptoms O
are O
characteristic O
for O
patients O
with O
VLCAD B
deficiency I
. O

Northern O
blot O
analysis O
and O
sequencing O
of O
cloned O
PCR O
amplified O
VLCAD O
cDNA O
from O
four O
unrelated O
patients O
with O
VLCAD B
deficiency I
showed O
that O
VLCAD O
mRNA O
was O
undetectable O
in O
one O
patient O
and O
that O
the O
other O
three O
have O
mutations O
in O
both O
VLCAD O
alleles O
. O

Where O
it O
is O
combined O
with O
a O
C6 B
- I
deficient I
gene O
, O
the O
serum O
C7 O
levels O
can O
be O
surprisingly O
high O
, O
possibly O
because O
there O
is O
no O
C6 O
generating O
C56 O
to O
consume O
the O
C7 O
. O

Complement O
C7 O
deficiency O
( O
C7D O
) O
is O
associated O
frequently O
with O
recurrent O
bacterial B
infections I
, O
especially O
meningitis B
caused O
by O
Neisseria O
meningitidis O
. O

HPRT O
- O
APRT O
- O
deficient O
mice O
are O
not O
a O
model O
for O
lesch B
- I
nyhan I
syndrome I
. O

Complete O
hypoxanthine O
- O
guanine O
phosphoribosyl O
- O
transferase O
( O
HPRT O
) O
deficiency O
in O
humans O
results O
in O
the O
Lesch B
- I
Nyhan I
syndrome I
which O
is O
characterized O
, O
among O
other O
features O
, O
by O
compulsive O
self O
- O
injurious O
behavior O
. O

HPRT B
- I
deficient I
mice O
generated O
using O
mouse O
embryonic O
stem O
cells O
exhibit O
none O
of O
the O
behavioral O
symptoms O
associated O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

Administration O
of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
APRT O
) O
in O
HPRT B
- I
deficient I
mice O
has O
produced O
the O
suggestion O
that O
deficiency O
of O
APRT O
in O
combination O
with O
HPRT O
- O
deficiency O
in O
mice O
may O
lead O
to O
self O
- O
mutilation O
behavior O
[ O
C O
. O
L O
. O
Wu O
and O
D O
. O
W O
. O
Melton O
( O
1993 O
) O
Nature O
Genet O
. O
3 O
, O
235 O
- O
240 O
] O
. O

Thus O
, O
APRT O
- O
HPRT O
- O
deficient O
mice O
, O
which O
are O
devoid O
of O
any O
purine O
salvage O
pathways O
, O
show O
no O
novel O
phenotype O
and O
are O
not O
a O
model O
for O
the O
behavioral O
abnormalities O
associated O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
as O
previously O
suggested O

METHODS O
Mutation O
analyses O
of O
the O
DPC4 O
gene O
were O
performed O
on O
complementary O
DNA O
samples O
from O
31 O
primary O
colorectal B
cancer I
specimens O
using O
a O
combination O
of O
polymerase O
chain O
reaction O
, O
single O
- O
strand O
conformation O
polymorphism O
, O
and O
DNA O
sequencing O
. O

RESULTS O
Four O
missense O
mutations O
producing O
amino O
acid O
substitutions O
and O
a O
somatic O
12 O
- O
base O
pair O
deletion O
in O
the O
coding O
region O
of O
the O
DPC4 O
gene O
were O
detected O
in O
the O
31 O
cancers B
( O
16 O
% O
; O
5 O
of O
31 O
) O
. O

Pleiotropic O
defects O
in O
ataxia B
- I
telangiectasia I
protein O
- O
deficient O
mice O
. O

We O
have O
generated O
a O
mouse O
model O
for O
ataxia B
- I
telangiectasia I
by O
using O
gene O
targeting O
to O
generate O
mice O
that O
do O
not O
express O
the O
Atm O
protein O
. O

Atm O
- O
deficient O
mice O
then O
exhibit O
many O
of O
the O
same O
symptoms O
found O
in O
ataxia B
- I
telangiectasia I
patients O
and O
in O
cells O
derived O
from O
them O
. O

The O
DCC O
protein O
and O
prognosis O
in O
colorectal B
cancer I
. O

Although O
the O
specific O
gene O
inactivated O
by O
this O
allelic O
loss O
has O
not O
been O
elucidated O
, O
the O
DCC O
( O
deleted O
in O
colorectal B
cancer I
) O
gene O
is O
a O
candidate O
. O

We O
investigated O
whether O
the O
expression O
of O
the O
DCC O
protein O
in O
tumor B
cells O
is O
a O
prognostic O
marker O
in O
colorectal B
carcinoma I
. O

The O
Cox O
proportional O
- O
hazards O
model O
was O
used O
to O
adjust O
for O
covariates O
including O
age O
, O
sex O
, O
tumor B
site O
, O
degree O
of O
tumor B
differentiation O
, O
and O
use O
of O
adjuvant O
therapy O
. O

In O
patients O
with O
stage O
II O
disease O
whose O
tumors B
expressed O
DCC O
, O
the O
five O
- O
year O
survival O
rate O
was O
94 O
. O

In O
stage O
II O
colorectal O
carcinomas O
, O
the O
absence O
of O
DCC O
identifies O
a O
subgroup O
of O
patients O
with O
lesions O
that O
behave O
like O
stage B
III I
cancers I
. O

Transporter O
- O
facilitated O
uptake O
of O
serotonin O
( O
5 O
- O
hydroxytryptamine O
or O
5 O
- O
HT O
) O
has O
been O
implicated O
in O
anxiety B
in O
humans O
and O
animal O
models O
and O
is O
the O
site O
of O
action O
of O
widely O
used O
uptake O
- O
inhibiting O
antidepressant O
and O
antianxiety O
drugs O
. O

Phenotypic O
and O
genotypic O
overlap O
between O
atelosteogenesis O
type O
2 O
and O
diastrophic B
dysplasia I
. O

Mutations O
in O
the O
diastrophic B
dysplasia I
sulfate O
transporter O
gene O
DTDST O
have O
been O
associated O
with O
a O
family O
of O
chondrodysplasias B
that O
comprises O
, O
in O
order O
of O
increasing O
severity O
, O
diastrophic B
dysplasia I
( O
DTD B
) O
, O
atelosteogenesis O
type O
2 O
( O
AO2 O
) O
, O
and O
achondrogenesis O
type O
1B O
( O
ACG1B O
) O
. O

To O
learn O
more O
about O
the O
molecular O
basis O
of O
DTDST O
chondrodysplasias O
and O
about O
genotype O
- O
phenotype O
correlations O
, O
we O
studied O
fibroblast O
cultures O
of O
three O
new O
patients O
one O
with O
AO O
- O
2 O
, O
one O
with O
DTD B
, O
and O
one O
with O
an O
intermediate O
phenotype O
( O
AO2 O
/ O
DTD B
) O
. O

In O
two O
patients O
( O
DTD B
and O
AO2 O
/ O
DTD B
) O
, O
no O
other O
structural O
mutation O
was O
found O
, O
but O
polymerase O
chain O
reaction O
amplification O
and O
single O
- O
strand O
conformation O
polymorphism O
analysis O
of O
fibroblast O
cDNA O
showed O
reduced O
mRNA O
levels O
of O
the O
wild O
- O
type O
DTDST O
allele O
these O
two O
patients O
may O
be O
compound O
heterozygotes O
for O
the O
" O
Finnish O
" O
mutation O
( O
as O
yet O
uncharacterized O
at O
the O
DNA O
level O
) O
, O
which O
causes O
reduced O
expression O
of O
DTDST O
. O

The O
presence O
of O
the O
DTDST O
R279W O
mutation O
in O
a O
total O
of O
11 O
patients O
with O
AO2 O
or O
DTD B
emphasizes O
the O
overlap O
between O
these O
conditions O
. O

Identification O
of O
WASP O
mutations O
, O
mutation O
hotspots O
and O
genotype O
- O
phenotype O
disparities O
in O
24 O
patients O
with O
the O
Wiskott B
- I
Aldrich I
syndrome I
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
an O
X O
- O
linked O
immunodeficiency O
disease O
caused O
by O
mutation O
in O
the O
recently O
isolated O
gene O
encoding O
WAS B
protein O
( O
WASP O
) O
, O
is O
known O
to O
be O
associated O
with O
extensive O
clinical O
heterogeneity O
. O

Cumulative O
mutation O
data O
have O
revealed O
that O
WASP O
genotypes O
are O
also O
highly O
variable O
among O
WAS B
patients O
, O
but O
the O
relationship O
of O
phenotype O
with O
genotype O
in O
this O
disease O
remains O
unclear O
. O

To O
address O
this O
issue O
we O
characterized O
WASP O
mutations O
in O
24 O
unrelated O
WAS B
patients O
, O
including O
18 O
boys O
with O
severe O
classical O
WAS B
and O
6 O
boys O
expressing O
mild O
forms O
of O
the O
disease O
, O
and O
then O
examined O
the O
degree O
of O
correlation O
of O
these O
as O
well O
as O
all O
previously O
published O
WASP O
mutations O
with O
disease O
severity O
. O

Similarly O
, O
while O
the O
cumulative O
data O
revealed O
a O
predominance O
of O
missense O
mutations O
among O
the O
WASP O
gene O
lesions O
observed O
in O
boys O
with O
isolated B
thrombocytopenia I
, O
missense O
mutations O
were O
not O
exclusively O
associated O
with O
milder O
WAS B
phenotypes O
, O
but O
also O
comprised O
a O
substantial O
portion O
( O
38 O
% O
) O
of O
the O
WASP O
gene O
defects O
found O
in O
patients O
with O
severe O
disease O
. O

These O
findings O
, O
as O
well O
as O
the O
detection O
of O
identical O
WASP O
mutations O
in O
patients O
with O
disparate O
phenotypes O
, O
reveal O
a O
lack O
of O
phenotype O
concordance O
with O
genotype O
in O
WAS B
and O
thus O
imply O
that O
phenotypic O
outcome O
in O
this O
disease O
cannot O
be O
reliably O
predicted O
solely O
on O
the O
basis O
of O
WASP O
genotypes O
. O
. O

Germline O
mutations O
in O
the O
3 O
' O
part O
of O
APC B
exon O
15 O
do O
not O
result O
in O
truncated O
proteins O
and O
are O
associated O
with O
attenuated O
adenomatous B
polyposis I
coli I
. O

Familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
an O
inherited O
predisposition O
to O
colorectal B
cancer I
characterized O
by O
the O
development O
of O
numerous O
adenomatous O
polyps O
predominantly O
in O
the O
colorectal O
region O
. O

Germline O
mutations O
in O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
are O
responsible O
for O
most O
cases O
of O
FAP B
. O

Mutations O
at O
the O
5 O
end O
of O
APC B
are O
known O
to O
be O
associated O
with O
a O
relatively O
mild O
form O
of O
the O
disease O
, O
called O
attenuated B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
. O

We O
identified O
a O
frameshift O
mutation O
in O
the O
3 O
part O
of O
exon O
15 O
, O
resulting O
in O
a O
stop O
codon O
at O
1862 O
, O
in O
a O
large O
Dutch O
kindred O
with O
AAPC B
. O

Western O
blot O
analysis O
of O
lymphoblastoid O
cell O
lines O
derived O
from O
affected O
family O
members O
from O
this O
kindred O
, O
as O
well O
as O
from O
a O
previously O
reported O
Swiss O
family O
carrying O
a O
frameshift O
mutation O
at O
codon O
1987 O
and O
displaying O
a O
similar O
attenuated O
phenotype O
, O
showed O
only O
the O
wild O
- O
type O
APC B
protein O
. O

Our O
study O
indicates O
that O
chain O
- O
terminating O
mutations O
located O
in O
the O
3 O
part O
of O
APC B
do O
not O
result O
in O
detectable O
truncated O
polypeptides O
and O
we O
hypothesize O
that O
this O
is O
likely O
to O
be O
the O
basis O
for O
the O
observed O
AAPC B
phenotype O
. O
. O

Over O
100 O
distinct O
disease O
- O
associated O
mutations O
have O
been O
identified O
in O
the O
breast B
- I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
. O

Loss O
of O
the O
wild O
- O
type O
allele O
in O
> O
90 O
% O
of O
tumors B
from O
patients O
with O
inherited O
BRCA1 O
mutations O
indicates O
tumor B
suppressive O
function O
. O

The O
low O
incidence O
of O
somatic O
mutations O
suggests O
that O
BRCA1 O
inactivation O
in O
sporadic O
tumors B
occurs O
by O
alternative O
mechanisms O
, O
such O
as O
interstitial O
chromosomal O
deletion O
or O
reduced O
transcription O
. O

The O
hereditary B
breast I
and I
ovarian I
cancer I
gene O
, O
BRCA1 O
, O
encodes O
a O
large O
polypeptide O
that O
contains O
the O
cysteine O
- O
rich O
RING O
motif O
, O
a O
zinc O
- O
binding O
domain O
found O
in O
a O
variety O
of O
regulatory O
proteins O
. O

The O
BARD1 O
/ O
BRCA1 O
interaction O
is O
disrupted O
by O
BRCA1 O
missense O
mutations O
that O
segregate O
with O
breast B
cancer I
susceptibility O
, O
indicating O
that O
BARD1 O
may O
be O
involved O
in O
mediating O
tumour B
suppression O
by O
BRCA1 O
. O
. O

45 O
- O
kilobases O
( O
kb O
) O
exon O
11 O
of O
the O
hereditary B
breast I
and I
ovarian I
cancer I
gene O
BRCA1 O
. O

The O
losses O
invariably O
involved O
the O
wild O
type O
allele O
derived O
from O
the O
unaffected O
parent O
, O
suggesting O
the O
inactivation O
of O
a O
tumor B
suppressor O
gene O
in O
this O
region O

In O
a O
study O
of O
G6PD B
deficient I
patients O
who O
presented O
with O
clinical O
favism B
in O
Spain O
, O
we O
have O
found O
a O
new O
polymorphic O
variant O
that O
we O
have O
called O
G6PD O
Malaga O
, O
whose O
only O
abnormality O
is O
a O
542 O
A O
- O
- O
> O
T O
( O
181 O
Asp O
- O
- O
> O
Val O
) O
mutation O
. O

G6PD O
Malaga O
is O
associated O
with O
enzyme B
deficiency I
( O
class O
III O
) O
, O
and O
the O
enzymic O
properties O
of O
G6PD O
Malaga O
and O
G6PD O
Santamaria O
are O
quite O
similar O
, O
indicating O
that O
in O
this O
case O
the O
effects O
of O
the O
two O
mutations O
are O
additive O
rather O
than O
synergistic O
. O

BRCA1 O
mutations O
cause O
increased O
risk O
for O
breast B
and I
ovarian I
cancer I
, O
frequently O
of O
early O
onset O
. O

Many O
different O
mutations O
occur O
in O
BRCA1 O
, O
including O
several O
examples O
of O
recurrent O
mutations O
, O
each O
of O
which O
accounts O
for O
a O
significant O
number O
of O
families O
with O
heritable O
cancer B
predisposition O
. O

These O
common O
mutations O
have O
an O
etiological O
role O
in O
many O
breast B
and I
ovarian I
cancer I
cases O
and O
provide O
the O
opportunity O
to O
examine O
genotype O
- O
phenotype O
correlations O
and O
genotype O
- O
environment O
interactions O
in O
individuals O
with O
the O
identical O
BRCA1 O
lesion O
. O

In O
all O
three O
cases O
, O
there O
is O
a O
strong O
family O
history O
of O
breast O
, O
ovarian O
, O
or O
other O
cancers O
possibly O
related O
to O
a O
BRCA1 O
defect O
and O
family O
members O
showed O
a O
high O
concordance O
of O
cancer B
incidence O
with O
the O
presence O
of O
R841W O
. O

The O
age O
of O
cancer B
onset O
was O
not O
always O
distinct O
from O
typical O
sporadic O
cases O
. O

Testing O
of O
a O
sample O
of O
413 O
unrelated O
individuals O
to O
examine O
the O
hypothesis O
that O
R841W O
might O
be O
a O
rare O
polymorphism O
detected O
one O
additional O
instance O
in O
a O
woman O
with O
breast B
cancer I
diagnosed O
at O
age O
77 O
years O
, O
and O
cancer B
in O
one O
parent O
. O

R841W O
is O
likely O
to O
be O
an O
etiologically O
significant O
lesion O
with O
involvement O
in O
close O
to O
1 O
% O
( O
95 O
% O
confidence O
interval O
of O
0 O
- O
1 O
. O
7 O
% O
) O
of O
all O
breast B
and I
ovarian I
cancers I
in O
this O
population O
. O

Ataxia B
- I
telangiectasia I
: O
founder O
effect O
among O
north O
African O
Jews O
. O

The O
ATM O
gene O
is O
responsible O
for O
the O
autosomal B
recessive I
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
characterized O
by O
cerebellar B
degeneration I
, O
immunodeficiency B
and O
cancer O
predisposition O
. O

A B
- I
T I
carriers O
were O
reported O
to O
be O
moderately O
cancer O
- O
prone O
. O

A O
wide O
variety O
of O
A B
- I
T I
mutations O
, O
most O
of O
which O
are O
unique O
to O
single O
families O
, O
were O
identified O
in O
various O
ethnic O
groups O
, O
precluding O
carrier O
screening O
with O
mutation O
- O
specific O
assays O
. O

However O
, O
a O
single O
mutation O
was O
observed O
in O
32 O
/ O
33 O
defective O
ATM O
alleles O
in O
Jewish O
A B
- I
T I
families O
of O
North O
African O
origin O
, O
coming O
from O
various O
regions O
of O
Morocco O
and O
Tunisia O
. O

This O
founder O
effect O
provides O
a O
unique O
opportunity O
for O
population O
- O
based O
screening O
for O
A B
- I
T I
carriers O
in O
a O
large O
Jewish O
community O
. O
. O

Mutation O
analysis O
of O
BRCA1 O
and O
BRCA2 O
in O
a O
male B
breast I
cancer I
population O
. O

A O
population O
- O
based O
series O
of O
54 O
male B
breast I
cancer I
cases O
from O
Southern O
California O
were O
analyzed O
for O
germ O
- O
line O
mutations O
in O
the O
inherited B
breast I
/ I
ovarian I
cancer I
genes O
, O
BRCA1 O
and O
BRCA2 O
. O

Nine O
( O
17 O
% O
) O
of O
the O
patients O
had O
a O
family O
history O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
in O
at O
least O
one O
first O
- O
degree O
relative O
. O

A O
further O
seven O
( O
13 O
% O
) O
of O
the O
patients O
reported O
breast B
/ I
ovarian I
cancer I
in O
at O
least O
one O
second O
- O
degree O
relative O
and O
in O
no O
first O
- O
degree O
relatives O
. O

Two O
male B
breast I
cancer I
patients O
( O
4 O
% O
of O
the O
total O
) O
were O
found O
to O
carry O
novel O
truncating O
mutations O
in O
the O
BRCA2 O
gene O
. O

Only O
one O
of O
the O
two O
male B
breast I
cancer I
patients O
carrying O
a O
BRCA2 O
mutation O
had O
a O
family O
history O
of O
cancer B
, O
with O
one O
case O
of O
ovarian B
cancer I
in O
a O
first O
- O
degree O
relative O
. O

The O
remaining O
eight O
cases O
( O
89 O
% O
) O
of O
male B
breast I
cancer I
with O
a O
family O
history O
of O
breast B
/ I
ovarian I
cancer I
in O
first O
- O
degree O
relatives O
remain O
unaccounted O
for O
by O
mutations O
in O
either O
the O
BRCA1 O
gene O
or O
the O
BRCA2 O
gene O
. O
. O

The O
TSG101 O
tumor B
susceptibility O
gene O
is O
located O
in O
chromosome O
11 O
band O
p15 O
and O
is O
mutated O
in O
human O
breast B
cancer I
. O

2 O
, O
a O
region O
proposed O
to O
contain O
tumor B
suppressor O
gene O
( O
s O
) O
, O
is O
mutated O
at O
high O
frequency O
in O
human O
breast B
cancer I
. O

In O
7 O
of O
15 O
uncultured O
primary O
human O
breast O
carcinomas O
, O
intragenic O
deletions O
were O
shown O
in O
TSG101 O
genomic O
DNA O
and O
transcripts O
by O
gel O
and O
sequence O
analysis O
, O
and O
mutations O
affecting O
two O
TSG101 O
alleles O
were O
identified O
in O
four O
of O
these O
cancers B
. O

No O
TSG101 O
defects O
were O
found O
in O
matched O
normal O
breast O
tissue O
from O
the O
breast B
cancer I
patients O
. O

Moderate O
intergenerational O
and O
somatic O
instability O
of O
a O
55 O
- O
CTG O
repeat O
in O
transgenic O
mice O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
associated O
with O
the O
expansion O
of O
a O
( O
CTG O
) O
n O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
( O
UTR O
) O
of O
the O
DM B
protein O
kinase O
gene O
( O
DMPK O
) O
. O

Moreover O
, O
mitotic O
instability O
analysis O
of O
different O
human O
DM B
tissues O
shows O
length O
mosaicism O
between O
different O
cell O
lineages O
. O

Missense O
mutations O
in O
the O
Fas O
gene O
resulting O
in O
autoimmune B
lymphoproliferative I
syndrome I
: O
a O
molecular O
and O
immunological O
analysis O
. O

The O
Fas O
/ O
Apo O
- O
1 O
receptor O
plays O
a O
crucial O
role O
in O
the O
regulation O
of O
apoptosis O
, O
as O
demonstrated O
by O
lymphoproliferation O
in O
MRL O
- O
lpr O
/ O
lpr O
mice O
and O
by O
the O
recently O
described O
autoimmune B
lymphoproliferative I
syndrome I
( O
ALPS B
) O
in O
humans O
, O
both O
of O
which O
are O
due O
to O
mutations O
in O
the O
Fas O
gene O
. O

We O
describe O
a O
novel O
family O
with O
ALPS B
in O
which O
three O
affected O
siblings O
carry O
two O
distinct O
missense O
mutations O
on O
both O
the O
Fas O
gene O
alleles O
and O
show O
lack O
of O
Fas O
- O
induced O
apoptosis O
. O

The O
children O
share O
common O
clinical O
features O
including O
splenomegaly B
and O
lymphadenopathy B
, O
but O
only O
one O
developed O
severe O
autoimmune O
manifestations O
. O

The O
ataxia B
- I
telangiectasia I
gene O
product O
, O
a O
constitutively O
expressed O
nuclear O
protein O
that O
is O
not O
up O
- O
regulated O
following O
genome O
damage O
. O

The O
product O
of O
the O
ataxia B
- I
telangiectasia I
gene O
( O
ATM O
) O
was O
identified O
by O
using O
an O
antiserum O
developed O
to O
a O
peptide O
corresponding O
to O
the O
deduced O
amino O
acid O
sequence O
. O

Truncated O
ATM O
protein O
was O
not O
detected O
in O
lymphoblasts O
from O
ataxia B
- I
telangiectasia I
patients O
homozygous O
for O
mutations O
leading O
to O
premature O
protein O
termination O
. O

Nonsense O
mutation O
in O
exon O
3 O
of O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
in O
a O
family O
with O
an O
unusual O
form O
of O
Pelizaeus B
- I
Merzbacher I
disease I
. O

We O
report O
a O
G O
- O
- O
> O
A O
transition O
at O
nucleotide O
431 O
of O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
results O
in O
a O
nonsense O
codon O
in O
a O
family O
with O
an O
unusual O
form O
of O
Pelizaeus B
- I
Merzbacher I
disease I
( O
PMD B
) O
. O

The O
clinical O
picture O
resembles O
somewhat O
that O
of O
X B
- I
linked I
spastic I
paraplegia I
( O
SPG B
) O
. O

It O
differs O
from O
this O
and O
both O
the O
classical O
and O
connatal O
forms O
of O
PMD B
in O
that O
it O
is O
relatively O
mild O
in O
form O
, O
onset O
is O
delayed O
beyond O
age O
2 O
years O
, O
nystagmus O
is O
absent O
, O
tremors O
are O
prominent O
, O
mental B
retardation I
is O
not O
severe O
, O
some O
patients O
show O
dementia O
or O
personality O
disorders O
, O
the O
disease O
is O
progressive O
rather O
than O
static O
in O
some O
, O
and O
several O
females O
show O
signs O
of O
disease O
. O

Common O
BRCA1 O
variants O
and O
susceptibility O
to O
breast B
and I
ovarian I
cancer I
in O
the O
general O
population O
. O

Most O
multiple O
case O
families O
of O
young O
onset O
breast B
cancer I
and O
ovarian B
cancer I
are O
thought O
to O
be O
due O
to O
highly O
penetrant O
mutations O
in O
the O
predisposing O
genes O
BRCA1 O
and O
BRCA2 O
. O

However O
, O
these O
mutations O
are O
uncommon O
in O
the O
population O
and O
they O
probably O
account O
for O
only O
a O
few O
percent O
of O
all O
breast B
cancer I
incidence O
. O

A O
much O
larger O
fraction O
of O
breast B
cancer I
might O
, O
in O
principle O
, O
be O
due O
to O
common O
variants O
which O
confer O
more O
modest O
individual O
risks O
. O

We O
have O
examined O
the O
frequency O
of O
four O
of O
these O
polymorphisms O
Gln356Arg O
, O
Pro871Leu O
, O
Glu1038Gly O
and O
Ser1613Gly O
in O
large O
series O
of O
breast B
and I
ovarian I
cancer I
cases O
and O
matched O
controls O
. O

Thus O
the O
most O
common O
polymorphisms O
of O
the O
BRCA1 O
gene O
do O
not O
make O
a O
significant O
contribution O
to O
breast B
or I
ovarian I
cancer I
risk O
. O

However O
, O
our O
data O
suggest O
that O
the O
Arg356 O
allele O
may O
have O
a O
different O
genotype O
distribution O
in O
breast B
cancer I
patients O
from O
that O
in O
controls O
( O
Arg356 O
homozygotes O
are O
more O
frequent O
in O
the O
control O
groups O
, O
P O
= O
0 O
. O
01 O
) O
, O
indicating O
that O
it O
may O
be O
protective O
against O
breast B
cancer I
. O

Kniest B
dysplasia I
: O
Dr O
. O
W O
. O

Kniest B
dysplasia I
is O
a O
severe O
chondrodysplasia B
caused O
by O
the O
defective O
formation O
of O
type O
II O
collagen O
. O

We O
report O
about O
Dr O
. O
Kniest O
, O
who O
first O
described O
the O
condition O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
age O
of O
50 O
years O
is O
severely O
handicapped O
with O
short B
stature I
, O
restricted O
joint O
mobility O
, O
and O
blindness B
but O
is O
mentally O
alert O
and O
leads O
an O
active O
life O
. O

This O
is O
in O
accordance O
with O
molecular O
findings O
in O
other O
patients O
with O
Kniest B
dysplasia I
and O
confirms O
, O
in O
the O
original O
patient O
, O
that O
the O
disorder O
is O
caused O
by O
small O
inframe O
deletions O
often O
due O
to O
exon O
skipping O
as O
a O
result O
of O
COL2A1 O
splice O
site O
mutations O
. O
. O

Cloning O
of O
the O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
gene O
, O
the O
key O
enzyme O
of O
alkaptonuria B
in O
mouse O
. O

This O
corresponds O
well O
to O
the O
previous O
assignment O
of O
the O
locus O
for O
the O
human O
alkaptonuria B
gene O
( O
AKU O
) O
to O
the O
same O
chromosomal O
region O
by O
multipoint O
linkage O
analysis O
. O

We O
therefore O
conclude O
that O
the O
HGO O
cDNA O
encodes O
the O
gene O
responsible O
for O
alkaptonuria B
. O

Mapping O
of O
homozygous O
deletions O
on O
human O
chromosome O
10q23 O
has O
led O
to O
the O
isolation O
of O
a O
candidate O
tumor B
suppressor O
gene O
, O
PTEN O
, O
that O
appears O
to O
be O
mutated O
at O
considerable O
frequency O
in O
human O
cancers B
. O

In O
preliminary O
screens O
, O
mutations O
of O
PTEN O
were O
detected O
in O
31 O
% O
( O
13 O
/ O
42 O
) O
of O
glioblastoma O
cell O
lines O
and O
xenografts O
, O
100 O
% O
( O
4 O
/ O
4 O
) O
of O
prostate B
cancer I
cell O
lines O
, O
6 O
% O
( O
4 O
/ O
65 O
) O
of O
breast B
cancer I
cell O
lines O
and O
xenografts O
, O
and O
17 O
% O
( O
3 O
/ O
18 O
) O
of O
primary O
glioblastomas O
. O

These O
homologies O
suggest O
that O
PTEN O
may O
suppress O
tumor B
cell O
growth O
by O
antagonizing O
protein O
tyrosine O
kinases O
and O
may O
regulate O
tumor B
cell O
invasion O
and O
metastasis O
through O
interactions O
at O
focal O
adhesions O
. O
. O

The O
Schwartz O
- O
Jampel O
syndrome O
( O
SJS O
; O
chondrodystrophic O
myotonia O
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively O
inherited O
condition O
defined O
by O
myotonia B
, O
short B
stature I
, O
and O
bone O
dysplasia O
. O

We O
found O
that O
a O
group O
of O
patients O
have O
mild O
skeletal O
changes O
which O
may O
be O
secondary O
consequences O
of O
myotonia B
, O
while O
another O
group O
of O
patients O
appear O
to O
have O
primary O
bone O
dysplasia O
with O
myotonia B
. O

We O
tentatively O
isolate O
three O
different O
types O
of O
SJS O
type O
1A O
, O
usually O
recognized O
in O
childhood O
, O
with O
moderate O
bone O
dysplasia O
, O
corresponding O
to O
the O
original O
descriptions O
of O
Schwartz O
, O
Jampel O
and O
Aberfeld O
; O
type O
1B O
, O
similar O
to O
type O
1A O
but O
recognizable O
at O
birth O
, O
with O
more O
pronounced O
bone O
dysplasia O
resembling O
Kniest B
dysplasia I
; O
and O
type O
2 O
, O
manifest O
at O
birth O
, O
with O
increased O
mortality O
and O
bone O
dysplasia O
resembling O
Pyle O
disease O
. O

Mutations O
in O
the O
WT1 O
gene O
were O
anticipated O
to O
explain O
the O
genetic O
basis O
of O
the O
childhood O
kidney O
cancer O
, O
Wilms B
tumour I
( O
WT B
) O
. O

While O
only O
5 O
% O
of O
sporadic O
Wilms O
tumours O
have O
intragenic O
WT1 O
mutations O
, O
> O
90 O
% O
of O
patients O
with O
the O
Denys B
- I
Drash I
syndrome I
( O
renal O
nephropathy O
, O
gonadal O
anomaly O
, O
predisposition O
to O
WT O
) O
carry O
constitutional O
intragenic O
WT1 O
mutations O
. O

The O
incidence O
of O
PAX6 O
mutation O
in O
patients O
with O
simple O
aniridia B
: O
an O
evaluation O
of O
mutation O
detection O
in O
12 O
cases O
. O

Twelve O
aniridia B
patients O
, O
five O
with O
a O
family O
history O
and O
seven O
presumed O
to O
be O
sporadic O
, O
were O
exhaustively O
screened O
in O
order O
to O
test O
what O
proportion O
of O
people O
with O
aniridia B
, O
uncomplicated O
by O
associated O
anomalies O
, O
carry O
mutations O
in O
the O
human O
PAX6 O
gene O
. O

To O
identify O
the O
genetic O
basis O
of O
C9 B
deficiency I
, O
we O
developed O
an O
approach O
using O
exon O
- O
specific O
PCR O
and O
direct O
DNA O
sequencing O
. O

As O
a O
cause O
of O
C9 B
deficiency I
, O
we O
found O
two O
different O
point O
mutations O
, O
both O
generating O
TGA O
stop O
codons O
in O
the O
coding O
sequence O
. O

In O
family O
studies O
of O
three O
first O
- O
degree O
relatives O
with O
heterozygous O
C9 B
deficiency I
, O
we O
demonstrated O
that O
the O
two O
mutations O
are O
segregating O
independently O
. O

BRCA1 O
mutations O
in O
women O
attending O
clinics O
that O
evaluate O
the O
risk O
of O
breast B
cancer I
. O

BACKGROUND O
To O
define O
the O
incidence O
of O
BRCA1 O
mutations O
among O
patients O
seen O
in O
clinics O
that O
evaluate O
the O
risk O
of O
breast B
cancer I
, O
we O
analyzed O
DNA O
samples O
from O
women O
seen O
in O
this O
setting O
and O
constructed O
probability O
tables O
to O
provide O
estimates O
of O
the O
likelihood O
of O
finding O
a O
BRCA1 O
mutation O
in O
individual O
families O
. O

METHODS O
Clinical O
information O
, O
family O
histories O
, O
and O
blood O
for O
DNA O
analysis O
were O
obtained O
from O
263 O
women O
with O
breast B
cancer I
. O

RESULTS O
BRCA1 O
mutations O
were O
identified O
in O
16 O
percent O
of O
women O
with O
a O
family O
history O
of O
breast B
cancer I
. O

Only O
7 O
percent O
of O
women O
from O
families O
with O
a O
history O
of O
breast B
cancer I
but O
not O
ovarian B
cancer I
had O
BRCA1 O
mutations O
. O

The O
rates O
were O
higher O
among O
women O
from O
families O
with O
a O
history O
of O
both O
breast B
and I
ovarian I
cancer I
. O

Among O
family O
members O
, O
an O
average O
age O
of O
less O
than O
55 O
years O
at O
the O
diagnosis O
of O
breast B
cancer I
, O
the O
presence O
of O
ovarian B
cancer I
, O
the O
presence O
of O
breast B
and I
ovarian I
cancer I
in O
the O
same O
woman O
, O
and O
Ashkenazi O
Jewish O
ancestry O
were O
all O
associated O
with O
an O
increased O
risk O
of O
detecting O
a O
BRCA1 O
mutation O
. O

No O
association O
was O
found O
between O
the O
presence O
of O
bilateral O
breast B
cancer I
or O
the O
number O
of O
breast B
cancers I
in O
a O
family O
and O
the O
detection O
of O
a O
BRCA1 O
mutation O
, O
or O
between O
the O
position O
of O
the O
mutation O
in O
the O
BRCA1 O
gene O
and O
the O
presence O
of O
ovarian B
cancer I
in O
a O
family O
. O

CONCLUSIONS O
Among O
women O
with O
breast B
cancer I
and O
a O
family O
history O
of O
the O
disease O
, O
the O
percentage O
with O
BRCA1 O
coding O
- O
region O
mutations O
is O
less O
than O
the O
45 O
percent O
predicted O
by O
genetic O
- O
linkage O
analysis O
. O

At O
the O
cytogenetic O
level O
this O
region O
is O
frequently O
deleted O
in O
a O
variety O
of O
different O
solid B
tumors I
, O
although O
not O
in O
pancreatic O
cancer O
. O

The O
frequency O
of O
codon O
50 O
mutation O
is O
roughly O
the O
same O
in O
pancreatic O
tumors O
as O
in O
the O
other O
types O
of O
tumors B
previously O
examined O
. O

Mutations O
in O
the O
ARP O
gene O
are O
thus O
commonly O
observed O
in O
pancreatic O
cancer O
, O
as O
well O
as O
many O
other O
cancers B
. O

Difficulties O
in O
the O
ascertainment O
of O
C9 B
deficiency I
: O
lessons O
to O
be O
drawn O
from O
a O
compound O
heterozygote O
C9 O
- O
deficient O
subject O
. O

The O
patient O
was O
shown O
to O
be O
heterozygous O
for O
DNA O
markers O
in O
the O
C6 O
, O
C7 O
and O
C9 O
region O
of O
chromosome O
5 O
and O
therefore O
appears O
to O
be O
a O
compound O
heterozygote O
for O
two O
uncharacterized O
C9 B
deficiency I
genes O
. O

We O
also O
suggest O
that O
C9 B
deficiency I
may O
be O
more O
common O
among O
Caucasians O
than O
has O
been O
reported O
. O
. O

Screening O
for O
ESR O
mutations O
in O
breast B
and I
ovarian I
cancer I
patients O
. O

In O
the O
present O
study O
, O
leukocyte O
DNA O
from O
143 O
patients O
with O
familial O
clustering O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
and O
tumour B
DNA O
from O
96 O
breast O
carcinomas O
were O
screened O
for O
base O
mutations O
in O
the O
estrogen O
receptor O
gene O
( O
ESR O
) O
. O

Three O
patients O
with O
a O
family O
history O
of O
cancer B
were O
carrying O
a O
Gly160Cys O
germline O
substitution O
. O

However O
, O
in O
the O
229 O
female O
controls O
in O
whom O
family O
history O
of O
cancer B
was O
known O
, O
one O
of O
two O
who O
had O
a O
sister O
with O
breast B
cancer I
was O
carrying O
the O
variant O
allele O
. O

Somatic O
mutations O
were O
not O
detected O
in O
any O
of O
the O
tumours B
studied O
, O
and O
the O
present O
data O
do O
not O
provide O
support O
for O
somatic O
ESR O
base O
mutations O
as O
an O
important O
mechanism O
for O
hormonal O
therapy O
resistance O
in O
estrogen O
receptor O
- O
positive O
breast O
carcinomas O
. O
. O

Molecular O
bases O
of O
C7 B
deficiency I
: O
three O
different O
defects O
. O

The O
molecular O
basis O
of O
C7 B
deficiency I
has O
been O
investigated O
in O
two O
Irish O
families O
and O
a O
number O
of O
Israeli O
families O
of O
Moroccan O
Sephardic O
Jewish O
origin O
. O

The O
Israeli O
C7 B
- I
deficient I
cases O
all O
share O
a O
C7 O
haplotype O
and O
are O
homozygous O
for O
a O
mis O
- O
sense O
mutation O
in O
exon O
9 O
. O

Classical B
galactosemia I
is O
caused O
by O
one O
common O
missense O
mutation O
( O
Q188R O
) O
and O
by O
several O
rare O
mutations O
in O
the O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
gene O
. O

To O
study O
the O
molecular O
genetics O
of O
classical O
and O
Duarte O
galactosemia O
, O
we O
analyzed O
the O
GALT O
mutations O
in O
30 O
families O
with O
classical B
galactosemia I
, O
in O
10 O
families O
with O
the O
D O
- O
2 O
variant O
and O
in O
3 O
individuals O
carrying O
the O
D O
- O
1 O
allele O
by O
denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
. O

DGGE O
detected O
59 O
of O
the O
60 O
classical O
galactosemia B
alleles O
. O

Eight O
novel O
candidate O
galactosemia B
mutations O
were O
found O
. O

We O
conclude O
that O
the O
mutations O
causing O
galactosemia B
are O
highly O
heterogeneous O
and O
that O
K285N O
is O
a O
second O
common O
galactosemia B
mutation O
in O
our O
population O
. O
. O

Isolation O
of O
full O
- O
length O
ATM O
cDNA O
and O
correction O
of O
the O
ataxia B
- I
telangiectasia I
cellular O
phenotype O
. O

A O
gene O
mutated O
in O
the O
human O
genetic B
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
ATM O
, O
was O
recently O
identified O
by O
positional O
cloning O
. O

We O
describe O
herein O
, O
to O
our O
knowledge O
, O
for O
the O
first O
time O
, O
the O
cloning O
of O
a O
full O
- O
length O
cDNA O
for O
ATM O
and O
correction O
of O
multiple O
aspects O
of O
the O
radio O
- O
sensitive O
phenotype O
of O
A B
- I
T I
cells O
by O
transfection O
with O
this O
cDNA O
. O

Overexpression O
of O
ATM O
cDNA O
in O
A B
- I
T I
cells O
enhanced O
the O
survival O
of O
these O
cells O
in O
response O
to O
radiation O
exposure O
, O
decreased O
radiation O
- O
induced O
chromosome O
aberrations O
, O
reduced O
radio O
- O
resistant O
DNA O
synthesis O
, O
and O
partially O
corrected O
defective O
cell O
cycle O
checkpoints O
and O
induction O
of O
stress O
- O
activated O
protein O
kinase O
. O

This O
correction O
of O
the O
defects O
in O
A B
- I
T I
cells O
provides O
further O
evidence O
of O
the O
multiplicity O
of O
effector O
functions O
of O
the O
ATM O
protein O
and O
suggests O
possible O
approaches O
to O
gene O
therapy O
. O
. O

Fusion O
genes O
resulting O
from O
alternative O
chromosomal O
translocations O
are O
overexpressed O
by O
gene O
- O
specific O
mechanisms O
in O
alveolar B
rhabdomyosarcoma I
. O

In O
the O
pediatric O
solid O
tumor O
alveolar B
rhabdomyosarcoma I
, O
a O
consistent O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
or O
variant O
t O
( O
1 O
; O
13 O
) O
( O
p36 O
; O
q14 O
) O
translocation O
generates O
PAX3 O
- O
FKHR O
or O
PAX7 O
- O
FKHR O
fusion O
proteins O
, O
respectively O
. O

Thus O
, O
gene O
- O
specific O
mechanisms O
were O
selected O
to O
overexpress O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
in O
alveolar B
rhabdomyosarcoma I
, O
presumably O
due O
to O
differences O
in O
regulation O
between O
the O
wild O
- O
type O
loci O
. O

Mutations O
in O
atm O
and O
p53 O
cause O
the O
human O
cancer O
- O
associated O
diseases O
ataxia B
- I
telangiectasia I
and O
Li B
- I
Fraumeni I
syndrome I
, O
respectively O
. O

Mice O
doubly O
null O
for O
atm O
and O
p53 O
exhibited O
a O
dramatic O
acceleration O
of O
tumour B
formation O
relative O
to O
singly O
null O
mice O
, O
indicating O
that O
both O
genes O
collaborate O
in O
a O
significant O
manner O
to O
prevent O
tumorigenesis O
. O

Finally O
- O
and O
in O
contrast O
to O
prior O
predictions O
- O
atm O
and O
p53 O
do O
not O
appear O
to O
interact O
in O
acute O
radiation O
toxicity O
, O
suggesting O
a O
separate O
atm O
effector O
pathway O
for O
this O
DNA O
damage O
response O
and O
having O
implications O
for O
the O
prognosis O
and O
treatment O
of O
human O
tumours B
. O
. O

Trinucleotide O
repeat O
expansion O
at O
the O
myotonic B
dystrophy I
locus O
reduces O
expression O
of O
DMAHP O
. O

Myotonic B
dystrophy I
, O
or O
dystrophia O
myotonica O
( O
DM B
) O
, O
is O
an O
autosomal O
dominant O
multisystem O
disorder O
caused O
by O
the O
expansion O
of O
a O
CTG O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
of O
the O
DMPK O
protein O
kinase O
gene O
on O
chromosome O
19q13 O
. O

Although O
the O
DM B
mutation O
was O
identified O
more O
than O
five O
years O
ago O
, O
the O
pathogenic O
mechanisms O
underlying O
this O
most O
prevalent O
form O
of O
hereditary O
adult O
neuromuscular O
disease O
remain O
elusive O
. O

Analysis O
of O
DMAHP O
expression O
in O
the O
cells O
of O
DM B
patients O
with O
loss O
of O
the O
hypersensitive O
site O
revealed O
a O
two O
- O
to O
fourfold O
reduction O
in O
steady O
- O
state O
DMAHP O
transcript O
levels O
relative O
to O
wild O
- O
type O
controls O
. O

Together O
, O
these O
results O
demonstrate O
that O
CTG O
- O
repeat O
expansions O
can O
suppress O
local O
gene O
expression O
and O
implicate O
DMAHP O
in O
DM B
pathogenesis O
. O

Constitutively O
methylated O
CpG O
dinucleotides O
as O
mutation O
hot O
spots O
in O
the O
retinoblastoma B
gene O
( O
RB1 O
) O
. O

A O
wide O
spectrum O
of O
mutations O
, O
ranging O
from O
point O
mutations O
to O
large O
deletions O
, O
have O
been O
described O
in O
the O
retinoblastoma B
gene O
( O
RB1 O
) O
. O

The O
von O
Hippel O
- O
Lindau O
tumor O
suppressor O
gene O
( O
VHL O
) O
has O
a O
critical O
role O
in O
the O
pathogenesis O
of O
clear O
- O
cell O
renal O
cell O
carcinoma O
( O
RCC B
) O
, O
as O
VHL O
mutations O
have O
been O
found O
in O
both O
von O
Hippel O
- O
Lindau O
disease O
- O
associated O
and O
sporadic O
RCCs O
. O

VEGF O
promoter O
- O
luciferase O
constructs O
were O
transiently O
cotransfected O
with O
a O
wild O
- O
type O
VHL O
( O
wt O
- O
VHL O
) O
vector O
in O
several O
cell O
lines O
, O
including O
293 O
embryonic O
kidney O
and O
RCC B
cell O
lines O
. O

Furthermore O
, O
endogenous O
VEGF O
mRNA O
levels O
were O
suppressed O
in O
permanent O
RCC B
cell O
lines O
expressing O
wt O
- O
VHL O
, O
and O
nuclear O
run O
- O
on O
studies O
indicated O
that O
VHL O
regulation O
of O
VEGF O
occurs O
at O
least O
partly O
at O
the O
transcriptional O
level O
. O

These O
observations O
support O
a O
new O
mechanism O
for O
VHL O
- O
mediated O
transcriptional O
repression O
via O
a O
direct O
inhibitory O
action O
on O
Sp1 O
and O
suggest O
that O
loss O
of O
Sp1 O
inhibition O
may O
be O
important O
in O
the O
pathogenesis O
of O
von B
Hippel I
- I
Lindau I
disease I
and O
RCC B
. O
. O

